Approval · Notice of Compliance 37697 · 2026
BREYANZI: Notice of Compliance 37697
Issued June 12, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37697
- Date
- June 12, 2026
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BREYANZI | Not yet assigned | — |
Medicinal ingredients
- LISOCABTAGENE MARALEUCEL 120,000,000 CAR-TC per DOSE